METHIXENE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H23NS.ClH.H2O
Molecular Weight	363.945
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.Cl.CN1CCCC(CC2C3=CC=CC=C3SC4=CC=CC=C24)C1

InChI

InChIKey=RAOHHYUBMJLHNC-UHFFFAOYSA-N

InChI=1S/C20H23NS.ClH.H2O/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20;;/h2-5,8-11,15,18H,6-7,12-14H2,1H3;1H;1H2

HIDE SMILES / InChI

Molecular Formula	C20H23NS
Molecular Weight	309.468
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/international/metixene.html | https://www.drugbank.ca/drugs/DB00340

Methixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as metixene is considered to relate to competitive antagonism of acetylcholine at muscarinic receptors in the corpus striatum, which then restores the balance.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL1907609 Sources: https://www.drugbank.ca/drugs/DB00340 \| https://www.ncbi.nlm.nih.gov/pubmed/3353357	Antagonist 2849		0.055 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: http://www.mims.com/india/drug/info/metixene?type=full&mtype=generic http://en.pharmacodia.com/web/drug/1_10382.html	Primary		Approved 8583	TREST Approved Use As monotherapy in Parkinson's disease

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY445438	https://www.001chemical.com/chem/7081-40-5
Acadechem	ACDS-027112	http://www.acadechemical.com/product/101811
Ambinter	Amb22491703	http://www.ambinter.com/reference/22491703
Aurora Fine Chemicals LLC	A17.949.735	http://online.aurorafinechemicals.com/info?ID=A17.949.735
ChemMol	99097062	http://www.chemmol.com/chemmol/99097062.html
DC Chemicals	DC20015	http://www.dcchemicals.com/product_show-DC20015.html
Debye Scientific	DB-071037	http://www.debyesci.com/cas_4969-02-2.html
eNovation Chemicals	D674515	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674515
Finetech	FT-0651957	http://www.finetechnology-ind.com/prod/detail/pub/4969-02-2.html
Finetech	FT-0653054	http://www.finetechnology-ind.com/prod/detail/pub/4969-02-2.html
Molcore	MC445438	https://www.molcore.com/product/7081-40-5
OChem	11454	http://www.ocheminc.com/index.php?act=psearch&pid=969M022
Sigma-Aldrich	PH010848_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph010848
Sinfoo Biotech	S011455	http://www.sinfoobiotech.com/product/1014853
Smolecule	S535279	http://www.smolecule.com/products/s535279
THE BioTek	bt-275788	https://www.thebiotek.com/product/inhibitors/bt-275788

PubMed

Title	Date	PubMed
Screening for new compounds with antiherpes activity.	1984-10	6517562
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.	1966-06	5964267

Patents

Sample Use Guides

In Vivo Use Guide

As monotherapy in Parkinson's disease Adult: As hydrochloride: Initially, 2.5 mg tid; increase gradually depending on clinical response to a total of 15-60 mg daily in divided doses.

Route of Administration: Oral

In Vitro Use Guide

When using ( -)3H-QNB to label muscarinic acetylcholine receptors in rat brain homogenates, the specific binding was of high affinity and saturable (apparent KD of 0.26k0.18 nM, B, of 2.09 k0.32 pmol/mg protein). Specific binding of 3H-QNB was competitively and in a concentration-dependent manner inhibited by methixene with the IC50-value 0.055 uM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:45:52 GMT 2025` Edited by `admin` on `Mon Mar 31 17:45:52 GMT 2025`
Record UNII	84L8XK6N1G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHIXENE HYDROCHLORIDE

Official Name

English

METIXENE HYDROCHLORIDE

Preferred Name

English

METIXENE HYDROCHLORIDE [MART.]

Common Name

English

METIXENE HYDROCHLORIDE [EP IMPURITY]

Common Name

English

TREST

Brand Name

English

METIXENE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

NSC-78194

Code

English

METHIXENE HCL

Common Name

English

SJ 1977

Code

English

METHIXENE HYDROCHLORIDE [USAN]

Common Name

English

METIXENE HYDROCHLORIDE [JAN]

Common Name

English

METHIXENE HYDROCHLORIDE MONOHYDRATE

Common Name

English

SJ-1977

Code

English

PIPERIDINE, 1-METHYL-3-(9H-THIOXANTHEN-9-YLMETHYL)-, HYDROCHLORIDE, MONOHYDRATE

Systematic Name

English

1-Methyl-3-(thioxanthen-9-ylmethyl)piperidine hydrochloride monohydrate

Systematic Name

English

METHIXENE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

METIXENE HYDROCHLORIDE MONOHYDRATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66880